ZENITHDRUG — Zenith Drugs Income Statement
0.000.00%
Last trade - 00:00- IN₹1.34bn
- IN₹1.60bn
- IN₹1.15bn
- 11
- 35
- 43
- 16
Annual income statement for Zenith Drugs, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2022 March 31st | 2023 March 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS |
| Standards: | IAS | IAS |
| Status: | Final | Final |
| Revenue | ||
| Total Revenue | 917 | 1,145 |
| Cost of Revenue | ||
| Gross Profit | 191 | 293 |
| Selling / General / Administrative Expenses | ||
| Depreciation and Amortization | ||
| Other Operating Expenses | ||
| Total Operating Expenses | 862 | 1,062 |
| Operating Profit | 55 | 83.7 |
| Total Net Non Operating Interest Income / Expense | ||
| Other Net Non Operating Costs | ||
| Net Income Before Taxes | 44.1 | 72.1 |
| Provision for Income Taxes | ||
| Net Income After Taxes | 31.3 | 51.5 |
| Minority Interest | ||
| Net Income Before Extraordinary Items | ||
| Net Income | 31.2 | 51.5 |
| Adjustments to Net Income | ||
| Income Available to Common Shareholders Excluding Extraordinary Items | ||
| Income Available to Common Shareholders Including Extraordinary Items | ||
| Diluted Net Income | 31.3 | 51.5 |
| Diluted Weighted Average Shares | ||
| Basic EPS Including Extraordinary Items | ||
| Diluted EPS Including Extraordinary Items | ||
| Diluted EPS Excluding Extraordinary Items | ||
| Normalised Income Before Taxes | ||
| Normalised Income After Taxes | ||
| Normalised Income Available to Common Shareholders | ||
| Diluted Normalised EPS | 1.82 | 3 |